Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia (2012)
- Authors:
- Levin, Raquel - Universidade Federal de São Paulo (UNIFESP)
- Almeida, Valéria - Universidade Federal de São Paulo (UNIFESP)
- Peres, Fernanda Fiel - Universidade Federal de São Paulo (UNIFESP)
- Calzavara, Mariana Bendlin - Universidade Federal de São Paulo (UNIFESP)
- Silva, Neide Derci da - Universidade Federal de São Paulo (UNIFESP)
- Suiama, Mayra Akimi - Universidade Federal de São Paulo (UNIFESP)
- Niigaki, Suzie Tamie - Universidade Federal de São Paulo (UNIFESP)
- Zuardi, Antonio Waldo
- Hallak, Jaime Eduardo Cecílio
- Crippa, José Alexandre de Souza
- Abilio, Vanessa Costhek - Universidade Federal de São Paulo (UNIFESP)
- USP affiliated authors: CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP ; ZUARDI, ANTONIO WALDO - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP
- Unidade: FMRP
- Subjects: CANNABIS (COMPONENTES;FARMACOLOGIA); ANTAGONISMO DE DROGAS; MODELOS ANIMAIS DE DOENÇAS; ESQUIZOFRENIA
- Language: Inglês
- Imprenta:
- Source:
- Título: Current Pharmaceutical Design
- ISSN: 1381-6128
- Volume/Número/Paginação/Ano: v. 18, n. 32, p. 4960-4965, 2012
-
ABNT
LEVIN, Raquel et al. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current Pharmaceutical Design, v. 18, n. 32, p. 4960-4965, 2012Tradução . . Acesso em: 21 jan. 2026. -
APA
Levin, R., Almeida, V., Peres, F. F., Calzavara, M. B., Silva, N. D. da, Suiama, M. A., et al. (2012). Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current Pharmaceutical Design, 18( 32), 4960-4965. -
NLM
Levin R, Almeida V, Peres FF, Calzavara MB, Silva ND da, Suiama MA, Niigaki ST, Zuardi AW, Hallak JEC, Crippa JA de S, Abilio VC. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current Pharmaceutical Design. 2012 ; 18( 32): 4960-4965.[citado 2026 jan. 21 ] -
Vancouver
Levin R, Almeida V, Peres FF, Calzavara MB, Silva ND da, Suiama MA, Niigaki ST, Zuardi AW, Hallak JEC, Crippa JA de S, Abilio VC. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current Pharmaceutical Design. 2012 ; 18( 32): 4960-4965.[citado 2026 jan. 21 ] - Interaction between cannabidiol (CBD) and 'delta 9'-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids [Carta]
- Cannabidiol induces autophagy via ERK1/2 activation in neural cells
- Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus
- Reprint of “Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (Danio rerio)”
- Cannabidiol was ineffective for manic episode of bipolar affective disorder
- Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test
- No association between electrodermal hyporesponsivity and enlarged cavum septi pellucidi in schizophrenia [Editorial]
- Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: reversal by cannabidiol
- Canabinoides: aspectos clínicos, farmacológicos e de neuroimagem
- Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
